United States Drug Patent 7,696,206: Claim Scope, Vardenafil Patent Landscape, and Generic Entry Risk

US Patent No. 7,696,206 covered vardenafil, the active pharmaceutical ingredient in Levitra, together with its hydrochloride salt, trihydrate, pharmaceutical compositions, and use in treating erectile dysfunction. Bayer AG was the principal patent holder. The patent had commercial significance because claims 2 and 3 specifically identified vardenafil hydrochloride and vardenafil hydrochloride trihydrate, the forms used in marketed Levitra products.

The patent’s nominal term expired on October 13, 2018, subject to any applicable patent-term adjustment or pediatric exclusivity. It no longer presents a current U.S. patent barrier to an abbreviated new drug application for vardenafil. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

What drug does US Patent 7,696,206 protect?

US 7,696,206 protects vardenafil and selected pharmaceutical forms of vardenafil.

Vardenafil is a phosphodiesterase type 5 inhibitor, or PDE5 inhibitor, used to treat erectile dysfunction. The compound is chemically identified in the patent as:

2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride.

The patent’s key commercial form is vardenafil hydrochloride trihydrate. Levitra tablets contain vardenafil hydrochloride in an oral solid dosage form. The patent does not claim the Levitra brand name, a specific tablet strength, a particular excipient system, or a specific manufacturing process.

What is the pharmacological target?

Vardenafil selectively inhibits PDE5, an enzyme that degrades cyclic guanosine monophosphate in penile tissue. PDE5 inhibition supports smooth-muscle relaxation and blood flow in response to sexual stimulation.

The patent is directed to the chemical entity and its therapeutic use. It does not establish exclusivity over PDE5 inhibition as a therapeutic concept. Sildenafil, tadalafil, avanafil, and other PDE5 inhibitors are outside the patent unless their structures independently fall within the claimed formula.

What are the claims of US Patent 7,696,206?

The six claims divide into four protection categories: the chemical genus, specifically named vardenafil salts, pharmaceutical compositions, and erectile-dysfunction treatment methods.

Claim	Subject matter	Practical scope
1	Compound of the patent formula, including a salt, hydrate, or hydrate of a salt	Broadest chemical claim
2	Vardenafil hydrochloride	Specific salt form
3	Vardenafil hydrochloride trihydrate	Specific solid-state form used commercially
4	Pharmaceutical composition containing a claim 1 compound and a pharmacologically acceptable formulating agent	Composition claim
5	Treatment of erectile dysfunction in a mammal using a claim 1 compound	Method-of-use claim
6	Claim 5 limited to treatment of a human	Human-treatment claim

How broad is claim 1?

Claim 1 is the principal chemical claim. It covers the compound represented by the patent’s structural formula and extends to a salt, hydrate, or hydrate of a salt.

The formula is broader than the named compound in claim 2. Depending on the substituent definitions and Markush variables shown in the issued patent, claim 1 can cover related analogues in the same chemical class. Claims 2 and 3 narrow the protection to commercially important vardenafil forms.

Because the structural formula supplied in the question is omitted, the precise boundaries of every Markush substituent in claim 1 cannot be reconstructed from the claim text alone. The issued patent must control for a complete atom-by-atom infringement analysis.

What does claim 2 cover?

Claim 2 covers vardenafil hydrochloride by chemical name. It is narrower than claim 1 but more readily applied in litigation because it identifies the active compound directly.

A product containing vardenafil hydrochloride would generally fall within claim 2 if the product includes the claimed chemical form. The claim does not require a particular tablet strength, dosage schedule, indication severity, or excipient.

What does claim 3 add?

Claim 3 covers vardenafil hydrochloride trihydrate. The claim is directed to a defined hydrate state rather than merely the hydrochloride salt.

This distinction matters because a generic manufacturer could seek to avoid a hydrate-specific claim by using a different solid form, an anhydrous form, or a formulation in which the claimed hydrate is not present. That strategy would not avoid claim 2 if the product still contains vardenafil hydrochloride within the scope of that claim.

What does claim 4 protect?

Claim 4 protects a pharmaceutical composition containing a claim 1 compound and a pharmacologically acceptable formulating agent.

The claim can reach tablets, capsules, or other pharmaceutical dosage forms containing the claimed active compound with conventional excipients. It does not require a particular excipient, dissolution profile, release mechanism, particle size, dosage, or manufacturing process.

The claim is therefore a composition claim, but not a detailed formulation patent in the modern sense. It does not independently create broad protection for every Levitra formulation feature.

What do claims 5 and 6 protect?

Claims 5 and 6 are method-of-use claims for treating erectile dysfunction. Claim 5 applies to a mammal; claim 6 narrows the method to humans.

These claims can be relevant to induced infringement where a generic product label instructs use for erectile dysfunction. Their practical force depends on the patent’s enforceability, Orange Book status, label language, and the date of infringement.

They do not prevent use of vardenafil for every possible medical purpose. They are limited to the claimed therapeutic method.

When did US Patent 7,696,206 expire?

The patent’s nominal expiration date was October 13, 2018, based on the earliest priority chain associated with the vardenafil patent family. FDA pediatric exclusivity could extend the effective regulatory protection period by six months, placing the relevant pediatric-exclusivity date in April 2019 if the statutory requirements applied to the listed product. The U.S. Patent and Trademark Office term-adjustment record and FDA Orange Book should control any historical launch-date analysis. [1, 2]

Milestone	Date or period
Earliest vardenafil family priority	October 13, 1997
US 7,696,206 filing	November 29, 2005
US 7,696,206 issue	April 13, 2010
Nominal patent expiration	October 13, 2018
Potential six-month pediatric extension	Approximately April 13, 2019
Current blocking status	Expired

The later U.S. filing date does not necessarily create a new 20-year term. Patent term generally runs from the earliest effective nonprovisional filing date in the priority chain, subject to statutory adjustments.

What was the Orange Book status of vardenafil?

FDA listed vardenafil-related patents for Levitra and its approved equivalents in the Orange Book. The principal patent estate included US 6,362,178 and US 7,696,206, together with regulatory exclusivity information applicable to the approved product. [2]

The Orange Book functioned as the principal regulatory notice mechanism for ANDA applicants. A generic applicant challenging a listed patent could make a Paragraph IV certification stating that the patent was invalid, unenforceable, or would not be infringed.

Because US 7,696,206 has expired, it no longer supports a current 30-month stay against an ANDA under the Hatch-Waxman framework. Historical litigation and settlement provisions remain relevant for launch chronology, but they do not restore an expired patent right.

Which companies challenged the vardenafil patents?

Vardenafil faced conventional ANDA-driven generic competition. Generic applicants, including Teva and other major manufacturers, challenged or prepared to challenge the listed Levitra patents through Paragraph IV certifications or related regulatory positions.

The typical litigation sequence was:

A generic applicant filed an ANDA for vardenafil tablets.
The applicant submitted a Paragraph IV certification against one or more listed patents.
Bayer and related rights holders filed patent-infringement litigation within the statutory period.
The litigation triggered a potential 30-month FDA approval stay.
The parties either litigated, settled, or allowed the dispute to proceed until patent expiry.

Public FDA records, court dockets, and settlement documents should be read together because an Orange Book listing alone does not establish that a patent was successfully enforced.

Was there a Paragraph IV challenge?

Yes. Vardenafil was subject to the same Paragraph IV challenge process that affected other major oral erectile-dysfunction products. The challenges focused on patent validity, enforceability, scope, and the effect of generic product labeling.

The key legal issue was whether a generic vardenafil product would infringe claims directed to the active ingredient, hydrochloride salt, trihydrate, composition, or erectile-dysfunction use.

What patent litigation affected vardenafil?

Historical litigation involving Bayer and generic applicants focused on the vardenafil patent family, including US 6,362,178 and US 7,696,206. The claims in US 7,696,206 created several possible infringement theories:

Direct infringement by manufacturing or selling vardenafil hydrochloride.
Direct infringement by supplying vardenafil hydrochloride trihydrate.
Composition infringement based on tablets containing the active compound and excipients.
Induced infringement based on a generic label instructing treatment of erectile dysfunction.

A generic applicant could challenge the patents by arguing that the claimed compound or salt was anticipated or obvious, that the claims were not adequately supported, or that the patent was unenforceable. It could also design around narrower claims by selecting a different solid form or relying on a formulation outside the claim language.

The commercial outcome depended heavily on settlement terms. Hatch-Waxman settlements can establish an agreed generic launch date before patent expiry, but the date is not necessarily evidence that the patent claims were weak or invalid. The relevant settlement documents and court orders must be reviewed for any authorized-launch, supply, license, or non-challenge provisions.

What formulations are protected by US 7,696,206?

The patent protects pharmaceutical compositions containing a claim 1 compound and an acceptable formulating agent. The scope includes conventional oral dosage forms when they contain the claimed vardenafil compound.

It does not, on the face of claim 4, require:

A particular vardenafil dose.
A specific tablet coating.
A particular dissolution rate.
A specific excipient combination.
Immediate-release or extended-release performance.
A defined particle-size distribution.
A particular packaging system.

The patent therefore provides baseline composition protection, not comprehensive formulation protection. A separate formulation patent would be needed to protect a distinctive dosage-form technology, such as an orally disintegrating tablet, a controlled-release system, a specific polymorph, or a manufacturing process.

Does US 7,696,206 protect the vardenafil trihydrate solid form?

Yes. Claim 3 expressly covers vardenafil hydrochloride trihydrate.

This is the patent’s most important solid-state claim. Solid-form claims can create a meaningful barrier when the marketed product uses the claimed hydrate and a generic applicant intends to reproduce that form.

The claim does not necessarily cover every physical mixture containing water and vardenafil. The relevant question is whether the product contains the claimed chemical hydrate as defined by the claim and supported by the patent specification. Characterization may require powder X-ray diffraction, thermogravimetric analysis, Karl Fischer water determination, spectroscopy, or other solid-state methods.

How strong is the patent estate for vardenafil?

The estate was commercially strong during the period before expiration because it combined several claim types around one active ingredient.

Estate component	Strength during term	Limitation
Chemical compound claim	High	Vulnerable to prior-art and obviousness attacks
Vardenafil hydrochloride claim	High	Depends on proof of the claimed salt form
Trihydrate claim	High for the marketed solid form	Potential design-around through another solid form
Composition claim	Moderate	Broad but limited formulation detail
ED method claims	Moderate	Label-dependent and potentially subject to divided-infringement issues
Manufacturing protection	Not established by the listed claims	Requires separate process claims

The estate’s strongest commercial claims were claims 2 and 3 because they tied the patent directly to the active pharmaceutical ingredient and its marketed hydrate. Claims 4 through 6 added litigation leverage but were more dependent on product composition and labeling.

After expiration, the estate has no continuing exclusionary value against ordinary U.S. generic entry. Patent strength must therefore be assessed historically rather than as a current blocking asset.

How does the vardenafil estate compare with sildenafil and tadalafil?

Vardenafil competed primarily with sildenafil, tadalafil, and later avanafil.

Drug	Originator	Core mechanism	Principal patent risk profile
Vardenafil	Bayer, with historical commercial participation by other partners	PDE5 inhibition	Compound, salt, hydrate, composition, and use claims
Sildenafil	Pfizer	PDE5 inhibition	Earlier compound and use patent estate; later generic entry
Tadalafil	Eli Lilly	PDE5 inhibition	Longer-lived compound, formulation, and method-of-use estate
Avanafil	Vivus, later commercial partners	PDE5 inhibition	Later-generation compound and formulation estate

Vardenafil’s patent estate was older than tadalafil’s and reached expiry earlier. Tadalafil retained greater commercial protection for longer because its development and patent chronology were later. Sildenafil had already established the commercial and regulatory pathway for PDE5 inhibitor generics.

No biosimilar pathway applies to any of these products because they are chemically synthesized small molecules. Generic manufacturers use ANDAs demonstrating pharmaceutical equivalence and bioequivalence.

What licensing deals affected commercial rights?

The patent itself does not grant a commercial license or establish the full chain of marketing rights. Bayer developed vardenafil and marketed Levitra through commercial arrangements that included other pharmaceutical companies in certain territories and periods.

Patent ownership, regulatory sponsorship, manufacturing rights, and distribution rights can be held by different entities. A patent assignment or exclusive license would need to be confirmed through USPTO assignment records and transaction documents. Commercial collaboration agreements do not necessarily transfer patent ownership.

The most relevant commercial entities associated with Levitra included Bayer and historical marketing partners such as GlaxoSmithKline. Those arrangements should be distinguished from ANDA settlements, which may grant a generic applicant an agreed launch date without transferring ownership of the patent estate.

What generic launch scenarios existed after patent expiry?

After expiration of the relevant vardenafil patents and any applicable pediatric exclusivity, generic launch could occur through several routes:

At-risk launch before final patent resolution

A generic applicant could launch after FDA approval while litigation remained unresolved. This exposed the applicant to damages and injunctive risk if the patent holder prevailed.

Authorized or settlement-based launch

A settlement could permit launch on an agreed date before nominal expiry. The agreement could also include supply terms, restrictions on authorized generic competition, or a license to the patent estate.

Post-expiry launch

After expiration, an ANDA applicant could launch without facing infringement liability based solely on the expired claims. Regulatory approval, manufacturing readiness, labeling, and commercial supply would remain separate requirements.

Vardenafil’s post-expiry competitive risk was higher than its pre-expiry risk because the core active-ingredient claims no longer blocked entry. Remaining barriers consisted mainly of ANDA approval timing, manufacturing scale, product quality, pricing, and market access.

What is the current commercial exposure from US 7,696,206?

The direct current revenue exposure from this patent is effectively zero as an enforceable U.S. exclusion right because the patent term has expired.

Its historical exposure was material. Levitra was a branded PDE5 inhibitor competing in a large erectile-dysfunction market. A generic launch could reduce branded volume, increase payer substitution, and compress net pricing. The patent’s expiry affected the brand, not the entire PDE5 category. Revenue could migrate to tadalafil, sildenafil, avanafil, over-the-counter or telehealth channels, and other branded or generic products.

A current valuation should not assign a remaining U.S. patent premium to US 7,696,206. Any residual value would arise from historical litigation rights, foreign counterparts, regulatory data, brand recognition, manufacturing know-how, or commercial agreements rather than from the expired U.S. claims.

Key Takeaways

US 7,696,206 covers vardenafil, the active ingredient in Levitra.
Claims 2 and 3 specifically cover vardenafil hydrochloride and vardenafil hydrochloride trihydrate.
Claim 4 covers pharmaceutical compositions containing the claimed compound.
Claims 5 and 6 cover treatment of erectile dysfunction, including treatment of humans.
The patent does not claim a specific tablet strength, excipient system, dissolution profile, or manufacturing process.
The nominal expiration date was October 13, 2018, with potential pediatric exclusivity extending protection into April 2019.
Historical Paragraph IV litigation involved Bayer and generic applicants, including Teva and other manufacturers.
The patent is expired and does not currently block U.S. generic vardenafil entry.
Vardenafil is a small molecule. Biosimilar provisions do not apply.
Current commercial value lies in the product, brand, regulatory status, supply chain, and related rights, not in enforceable exclusivity under US 7,696,206.

FAQs About US Patent 7,696,206 and Vardenafil

Is US 7,696,206 a formulation patent for Levitra?

No. It contains a broad pharmaceutical-composition claim, but it does not recite a detailed excipient mixture, release profile, or tablet manufacturing process.

Does claim 3 cover anhydrous vardenafil hydrochloride?

No. Claim 3 expressly identifies the trihydrate. An anhydrous form may avoid claim 3, but it could still implicate claim 2 or claim 1 depending on the precise chemical form and claim construction.

Can a generic company sell vardenafil after US 7,696,206 expired?

Yes, subject to FDA approval through the ANDA pathway and compliance with applicable regulatory requirements. The expired patent does not independently prevent launch.

Does a generic vardenafil label create method-of-use infringement risk?

It could have during the patent term if the label instructed treatment of erectile dysfunction within claims 5 or 6. That risk ended when the relevant claims expired.

Are foreign vardenafil patents expired on the same date as US 7,696,206?

Not necessarily. Foreign counterparts are governed by national patent laws, filing histories, patent-term adjustments, supplementary protection certificates, and local extensions. The U.S. expiration date cannot be applied automatically to Europe, Japan, Canada, or other jurisdictions.

References

Bayer Aktiengesellschaft. (2010). Piperazine derivatives and their use in the treatment of erectile dysfunction, U.S. Patent No. 7,696,206 B2. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2012). Levitra (vardenafil hydrochloride) prescribing information. FDA.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. USPTO.
Bayer HealthCare Pharmaceuticals Inc. (2003). Levitra (vardenafil hydrochloride) tablets prescribing information. U.S. Food and Drug Administration.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	197 50 085	Nov 12, 1997
Germany	198 12 462	Mar 23, 1998
Germany	198 40 289	Sep 04, 1998

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	013759	⤷ Start Trial
Argentina	035972	⤷ Start Trial
Austria	213246	⤷ Start Trial
Australia	1558799	⤷ Start Trial
Australia	738675	⤷ Start Trial
Bulgaria	104406	⤷ Start Trial
Bulgaria	65257	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,696,206

Summary for Patent: 7,696,206